Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Open-Label Study of Xolair (Omalizumab) in Peanut-Allergic Subjects Randomized to Study Drug in Study Q2788g (TOPS)

NCT00382148 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00382148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00382148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Open-Label Study of Xolair (Omalizumab) in Peanut-Allergic Subjects Randomized to Study Drug in Study Q2788g (TOPS)
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2006
Completion date
June 28, 2008
Enrollment
11 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

peanut hypersensitivity